Anti-Platelet and Anti-Coagulant Drugs (Lobel) - 11/7/16 Flashcards
Heparin
Heparin administration
Heparin vs Heparan Sulfate
Indirect thrombin inhibitor
Heparin = Antithrombin III activator (inhibits Xa)
Administration:
- NOT absorbed from GI tract – not effective orally
- Does not cross placenta or accumulate in milk of nursing mothers
- IV route for treatment of patients w/ active thrombosis or PE
Heparan Sulfate = component of ECM (not as strong of anticoag effect)
Antithrombotic mechanisms (4) 1/3
-
Intact endothelium
- Separates plasma factor VII from subendothelial tissue factor
-
Blood flow
- Clears activated coagulation factors
-
Prostacyclin (PGI2)
- Inhibits platelets
-
t-PA
- Activates plasminogen
- Plasmin degrades fibrin
Antithrombotic mechanisms (2/3)
antithrombin (ATIII)
- Natural blood thinner
- Antithrombin inhibits
- Thrombin (IIa)
- Factor Xa
- Factor IXa
- Activated by: endothelial cell heparan sulfate
Antithrombotic mechanisms (3/3)
Protein C / Protein S / Thrombomodulin
- Degrade factors Va and VIIIa
- Protein C or S deficiency → Inc. risk for venous thrombosis
Complications of heparin therapy
- Major bleeding (5-10 day course)
- Osteoporosis
- Heparin resistance
- Heparin-induced thrombocytopenia (deficiency of platelets in blood)
Indirect thrombin inhibitors:
Heparin
Enoxaparin
Fondaparinux
Enoxaparin
-
Compared to heparin
- Less inhibition of thrombin
- Efficiently inhibit factor Xa activity
- Less effect on vascular permeability
- Less bound to plasma proteins
- Longer half life (~4.5 h), less frequent dosing
- Contraindicated in patients with HIT
- Typically used in:
- Prevention of DVT in postop period
- Treatment of acute venous thromboembolic disease and acute coronary syndromes
Fondaparinux
- Long half-life (17-21 h)
- 100% bioavailable after single, daily, subcutaneous dose
- Renal clearance, should not be given to patients with renal impairment
- Does not cause HIT
Direct thrombin inhibitors- parenteral
Desirubin
Bivalirudin
Argatroban
Desirubin
- 65 aa protein found in medicinal leech
- Most potent known inhibitor of thrombin
- Action is independent of antithrombin III
- Does not cause thrombocytopenia
- Renal clearance
- Bind catalytic site and exosite I of thrombin
Bivalirudin
- Short half life (~25 min)
- Clearance: renal and metabolic
- Bind catalytic site and exosite I of thrombin
Argatroban
- Used as anticoagulant in patients with heparin-induced thrombocytopenia (HIT)
- Half life: 40-50 min
- Binds only at active site of thrombin
Oral Anticoagulant
Warfarin
- Inhibits biosynthesis of vitamin K-dependent zymogens
- Procoagulant:
- Prothrombin
- Factor VII
- Factor IX
- Factor X
- Anticoagulant:
- Protein C
- Protein S
- Procoagulant:
Warfarin mechanism
Adverse effects of Warfarin therapy
- Bleeding
-
Birth defects and abortion
- Skeletal and CNS abnormalities (hypoplastic nose, flat face, altered calcification)
- Contraindicated during pregnancy (heparin may be used)
-
Skin necrosis
- Microvascular thrombosis
- May occur in patients with heterozygous protein C or S deficiency if high initial dose is used or heparin overlap is inadequate
New/Novel Direct Oral Anticoagulants (NOACs)
Dabigatran: thrombin inhibitor
Rivaroxaban, Apixaban, Edoxaban: Xa inhibitors
- Non-inferiority/superiority to Warfaran
- Similar/less intracranial bleeding
- Similar overall bleeding
- Similar uses to warfarin but not approved for thrombus prophylaxis with synthetic heart valves
Fibrinolysis
Process of breaking down fibrin
Conversion of plasminogen to plasmin
Physiologically, activity of activated plasmin is restrict to the clot
- Activators are effective mainly on plasminogen absorbed to fibrin
- Plasmin which escape into circulation is inactivated
Fibrinolytic drugs:
Altephase
Half-life
Approved uses
Alteplase: recominbant tissue plasminogen activity (tPA)
Half-life: ~5 min in plasma
Approved uses:
- Acute MI
- Acute ischemic stroke
- PE
- Central venous catheter occlusion
Contraindications to fibrinolytic therapy
- Prior intracranial hemorrhage
- Known structural cerebral vascular lesion
- Known malignant intracranial neoplasm
- Ischemic stroke within 3 months
- Suspected aortic dissection
- Active bleeding (excluding menses)
- Significant closed-head trauma or facial trauma within 3 mo
Antiplatelet agents
Drug targets (3)
- Inhibition of prostaglandin metabolism
- Inhibition of ADP-induced platelet aggregation
- BLockage of GP IIb/IIIa receptors on platelets